Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
作者信息
Glund Stephan, Reilly Paul, van Ryn Joanne, Stangier Joachim
机构信息
Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany.
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
出版信息
Clin Pharmacokinet. 2017 Feb;56(2):209-210. doi: 10.1007/s40262-016-0493-1.
Abstract
摘要
相似文献
1
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".作者对卡迈勒等人的回复：“年龄和肾功能对依达赛珠单抗药代动力学及依达赛珠单抗介导的达比加群抗凝活性逆转的影响：一项随机、双盲、交叉1b期研究”
Clin Pharmacokinet. 2017 Feb;56(2):209-210. doi: 10.1007/s40262-016-0493-1.
2
Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Clin Pharmacokinet. 2017 Feb;56(2):207-208. doi: 10.1007/s40262-016-0481-5.
3
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.年龄和肾功能对依达赛珠单抗药代动力学及依达赛珠单抗介导的达比加群抗凝活性逆转作用的影响：一项随机、双盲、交叉1b期研究
Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0.
4
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.依达赛珠单抗，一种达比加群的特异性逆转剂：作用机制、药代动力学和药效学，以及在1期受试者中的安全性和有效性。
Am J Emerg Med. 2016 Nov;34(11S):26-32. doi: 10.1016/j.ajem.2016.09.050. Epub 2016 Sep 28.
5
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.依达赛珠单抗，一种达比加群的特异性逆转剂：作用机制、药代动力学和药效学以及1期受试者的安全性和有效性。
Am J Med. 2016 Nov;129(11S):S64-S72. doi: 10.1016/j.amjmed.2016.06.007. Epub 2016 Aug 26.
6
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.达比加群逆转剂依达赛珠单抗在I期研究中的免疫原性评估。
Br J Clin Pharmacol. 2017 Aug;83(8):1815-1825. doi: 10.1111/bcp.13269. Epub 2017 Apr 6.
7
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.依达赛珠单抗用于逆转达比加群相关抗凝作用
Ann Pharmacother. 2016 Oct;50(10):847-54. doi: 10.1177/1060028016659504. Epub 2016 Jul 7.
8
Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.依达赛珠单抗，一种用于直接逆转达比加群作用的人源化单克隆抗体片段。
J Pharm Pract. 2015 Dec;28(6):548-54. doi: 10.1177/0897190015615248.
9
Evidence Supporting Idarucizumab for the Reversal of Dabigatran.支持艾达司珠单抗用于达比加群逆转的证据。
Am J Med. 2016 Nov;129(11S):S73-S79. doi: 10.1016/j.amjmed.2016.06.008. Epub 2016 Aug 25.
10
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.达比加群酯逆转剂依达鲁珠单抗在健康男性志愿者中的安全性、耐受性和疗效：一项随机、安慰剂对照、双盲的 1 期临床试验。
Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15.
引用本文的文献
1
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.直接口服抗凝剂治疗择期手术和急症出血的管理。
Curr Cardiol Rep. 2017 Oct 24;19(12):124. doi: 10.1007/s11886-017-0930-2.
本文引用的文献
1
Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Clin Pharmacokinet. 2017 Feb;56(2):207-208. doi: 10.1007/s40262-016-0481-5.
2
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.年龄和肾功能对依达赛珠单抗药代动力学及依达赛珠单抗介导的达比加群抗凝活性逆转作用的影响：一项随机、双盲、交叉1b期研究
Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0.
3
Idarucizumab for Dabigatran Reversal.达比加群酯逆转剂依达鲁珠单抗。
N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
4
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.一项在健康志愿者中开展的随机研究，旨在调查达比加群的特异性解毒剂艾达司珠单抗的安全性、耐受性和药代动力学。
Thromb Haemost. 2015 May;113(5):943-51. doi: 10.1160/TH14-12-1080. Epub 2015 Mar 19.
Zotero 插件